Participants 587 607 3
pharmacokinetic (PK)
Participants 626 648 3
BDDrFVIII formulations
Participants 830 860 4
in patients with haemophilia A
Participants 900 1020 4
series of blood samples were collected over a period of 48 h after i.v. administration of each of the FVIII preparations
